Atazanavir

🧮 Dose calculator

HIV-1 infection (treatment) · Regimen source: FDA Reyataz · 2.3

• • Always with other antiretrovirals (unless a complete regimen). FDA Reyataz · 2.3
• • Treatment-naive alternative: 400 mg unboosted. Separate from H2 blockers/PPIs per label. Renal tests before and during therapy. FDA Reyataz · 2.3FDA Reyataz · 2.1FDA Reyataz · 2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Reyataz · 8.1

  “Risk Summary Atazanavir has been evaluated in a limited number of women during pregnancy.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Reyataz · 8.2

  “Risk Summary Atazanavir has been detected in human milk.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Reyataz · 8.4

  “REYATAZ is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1, 3 months of age and older weighing at least 5 kg.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Reyataz · 8.5

  “In general, appropriate caution should be exercised in the administration and monitoring of REYATAZ in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.